Brain cancer at 21 forced Matthew Zachary into the American healthcare system decades before he understood its economics, incentives, and failures. At 52, he reflects on how surviving long enough to see the whole machine clearly led to writing We the Patients.

Cancer patients increasingly absorb the financial risk of surviving disease in America. A brain cancer survivor examines how healthcare incentives, insurance design, and policy decisions shifted instability onto patients and families while institutions protect margins.

Patients now need executive level skills to survive diagnosis, treatment, and access. This essay featuring Kathy Giusti breaks down how healthcare incentives create that reality, who benefits, who pays, and what must change to reduce risk and restore accountability.

Thirty years after brain cancer, Matthew Zachary returned to the piano at Merkin Hall for MZLIVE, a night that became far more than a concert. Survivors, advocates, clinicians, and healthcare leaders confronted what survivorship actually costs and what the system still refuses to see

We the Patients officially launches today and is already in its second printing before release day. Matthew Zachary shares why readers across healthcare, advocacy, and survivorship circles are responding so strongly to a book that names the realities patients live through every day.

Mark Cuban attacks healthcare through pricing transparency and market discipline. I would attack it through patient infrastructure, legal protection, accountability, and civic power. Together, those strategies could finally begin realigning the incentives driving American healthcare.

Millions of eczema patients increasingly distrust the treatments medicine tells them to rely on. Matthew Zachary examines topical steroid withdrawal, chronic inflammation, patient distrust, and the healthcare incentives driving one of medicine’s fastest growing credibility crises

Hospitals blame insurers. Insurers blame hospitals. Patients finance the entire system through premiums, deductibles, debt, and confusion. Matthew Zachary examines the incentive structures, financial flows, and institutional dependencies that keep American healthcare expensive, opaque, and exhausting.

A conference on patient advocacy with zero patients on the panel says everything. The industry keeps explaining itself while excluding the people who live the consequences. Here is what that looks like and why it keeps happening.

A ruptured brain aneurysm triggered elite emergency care that saved a life. Insurance policy still blocks preventive screening for her child. This piece explains how US healthcare pays for catastrophe and delays detection, and what must change before the next bleed.

23,000 people follow me on LinkedIn. They are patients, caregivers, and clinicians dealing with insurance denials, medical debt, and delays in care. Here is what they are seeing every day and why it reflects a much larger problem across US healthcare.

Prior authorization persists because it works for the system that created it. This essay explains how cost control, risk management, and delay shape patient outcomes, why reform keeps falling short, and what must change to align financial incentives with timely care.

Only 0.2% of patients appeal insurance denials, yet 80% succeed. This article examines how even small increases in appeals could shift insurer behavior, raise costs, influence Wall Street expectations, and reshape the economics of American healthcare.

American healthcare delays care and denies treatment by design. Insurance rules, prior authorization, and administrative barriers control access to care, often slowing or blocking what doctors recommend and patients need.

A 30 year brain cancer survivor breaks down how insurance delays, denials, and red tape harm patients by design. This is not dysfunction. This is the business model.

Mark Cuban is stepping in where insurers fail, funding care and challenging the system. But real change will not come from policy alone. A unified patient voting bloc could reshape healthcare power in America.

Matthew Zachary joins Humanity Rx to break down how modern cancer care improves survival while leaving patients exposed to medical debt, prior authorization delays, and financial risk, and why policy change depends on organized patient power.

When an insurer labels trigeminal nerve blocks investigational, patients may face brain surgery instead. This essay examines how coverage policy, coding decisions, and actuarial incentives shape care for trigeminal neuralgia and what must change to align patient protection with economic logic.

Millions cycle through eczema treatments that calm symptoms but never fix the cause. This essay explains how payment models, regulation, and product marketing keep patients trapped in repeat care instead of long term prevention.

Blue Cross Blue Shield settled a 2.67 billion antitrust lawsuit in 2020 after restricting competition for more than a decade. Payments begin in 2026. Six years later, customers get checks while insurers move on. Here is what happened and why it keeps happening.